

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare



CIN No: L24239MH1987PLC043662

August 16, 2019

To
BSE Ltd.,
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street - Fort,
Mumbai - 400 001

Ref.: BSE Scrip Code - 539730

Subject: Newspaper Advertisement of the Financial Statements for Quarter ended June 2019

Dear Sir / Madam,

In compliance to Regulation 47(1)(b) of SEBI Listing Regulations, 2015; we enclose herewith the copies of the Newspaper cuttings of the Financials Results of the Company for the Quarter ended June 2019; as approved by the Board in its Meeting held on Tuesday, August 13, 2019; published in Business Standard & Mumbai Lakshadeep newspaper(s) on August 15, 2019.

Kindly take the same on your Records.

Thanking you,

For Fredun Pharmaceuticals Limited



Priyanka Chaturvedi
Company Secretary Cum Compliance Officer
Membership No.: A55917

Encl. - A/a

Office Address: Manoj Industrial Premises, G.D. Ambekar Marg, Wadala (W), Mumbai - 400 031, (INDIA)

Phone No.: 91-22- 4031 8111 Fax : 91-22-4031 8133

Factory Address: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com Web: www.fredungroup.com



FREDUN PHARMACEUTICALS LIMITED

CIN: L24239MH1987PLC043662

Registered Office: 26, Manoj Industrial Premises, G.D. Ambekar Marg, Wadala, Mumbai - 400 031

Phone Number: +91 22 4031 8111 | Fax: +91 22 4031 8133

Email: business@fredungroup.com | Website: www.fredungroup.com

EXTRACT OF THE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019*

(Rs. In Lakhs)

Sr. No.	Particulars	Quarter Ended		Year ended	
		June 2019 (Unaudited)	March 2019 (Audited)	June 2018 (Unaudited)	March 2019 (Audited)
1.	Total Income from Operations	2832.41	3222.86	1651.73	9740.30
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	23.34	282.02	(62.94)	616.18
3.	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	23.34	282.02	(62.94)	616.18
4.	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	23.34	111.84	(62.94)	446.00
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	23.34	111.84	(62.94)	446.00
6.	Equity Share Capital	398.96	398.96	344.72	398.96
7.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	3499.95
8.	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) -				
	1. Basic:	0.59	2.80	00	11.17
	2. Diluted:	0.59	2.80	00	11.17

Note:

* This is in reference to our Newspaper article published yesterday i.e., August 14, 2019 wherein inadvertently the extracts were titled for March 2019. The title shall be read as "Extract of the Unaudited Financials for the Quarter ended June 30, 2019".

a) The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the website of the BSE Ltd. at www.bseindia.com and of the Company at www.fredungroup.com

b) # - Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable.

For Fredun Pharmaceuticals Limited

Sd/-

Daulat Medhora

Jt. Managing Director

Place : Mumbai

Date : August 13, 2019

Goregaon

EXTRA

Sr. No.

1 Total i

2 Net Pr

Excep

3 Net Pr

(after t

4 Net Pr

(after t

5 Total C

[Comp

Other t

6 Paid up

7 Earning

a. Ba

b. Ba

Note : The a

Stock Exch

Regulations

The full form

1) On the BS

2) On Comp

Date : 13/08

Place : Mun

ISO 9001:2015
COMPANY

R
(RS. IN LAKHS)

YEAR ENDED
31-03-2018
Audited
(Ind AS)

8,391.23

42.63

42.63

42.25

36.02

420.68

1,102.74

0.86

0.86

the Stock
s) Regulations
nges websites,

inies Act, 2013

or of the Board,
Rubber Limited,
Sd/-

(amesh Reddy)
airman & CFO,
IN : 00025101.

CHEMTECH INDUSTRIAL VALVES LIMITED

REGD OFFICE: 105, HIRANANDANI INDUSTRIAL ESTATE, OPP. KANJURMARG RAILWAY STATION

KANJURMARG (WEST), MUMBAI - 400 078

CIN: L29299MH1997PLC105108

Email: investors@chemtechvalves.com

Tel: 022258395

Extract Statement of Unaudited Financial Results for the quarter ended June 30 2019

(Rs. in Lakhs)

Sr. No.	Particulars	Quarter Ended		Year Ended	
		30-Jun-19 (Unaudited)	31-Mar-19 (Audited)	30-Jun-18 (Unaudited)	31-Mar-19 (Audited)
1.	Total Income from Operations (Net)	404.09	541.02	184.07	1666.90
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(41.48)	92.11	(56.83)	0.74
3.	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	(41.48)	92.11	(56.83)	0.74
4.	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	(41.80)	69.82	(17.21)	23.31
5.	Total Comprehensive Income for the period (after tax) and Other Comprehensive Income (after tax)	(41.80)	69.82	(17.21)	23.31
6.	Paid up equity share Capital	1,148.73	1,148.73	1,148.73	1,148.73
7.	Other Equity				(383.28)
8.	Earning per share (EPS) FV of Rs.10/- each (Face value Rs.10 per share)				
	(a) Basic EPS	(0.36)	0.61	(0.15)	0.20
	(b) Diluted EPS	(0.36)	0.61	(0.15)	0.20

Note: The above is an extract of the detailed format of unaudited Financial Results for the quarter ended on June 30 2019 filed with the stock exchange under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited Financial Results for the quarter ended June 30 2019 are available on the Stock Exchange web sites viz., (www.bseindia.com) and Company's website (www.chemtechvalves.com).

Date :13/08/2019

Place: Mumbai

For Chemtech Industrial Valves Limi

Harsh Pradeep Badkur

Managing Director



वेबसाइट:

वित्तीय निष्कर्षाचा अहवाल

(रु. लाखात)

एकत्रित			
संपलेली विमाही		संपलेले वर्ष	
परिधीत	लेखापरिधीत	अलेखापरिधीत	लेखापरिधीत
३१.०३.१९	३१.०३.१९	३०.०६.१८	३१.०३.१९
१.०३	१११२०.४९	१३६९१.३९	५३४९१.८४
८८	(७५२.९६)	(२१०.२८)	(११७०.०५)
८३	(०.२२)	(४९.८३)	(६०१.५६)
०६	(७५२.७६)	(१६७.४६)	(९६८.४९)
७३	(७४२.५६)	(१६२.४२)	(९५७.९६)
३१	३३८६.३१	३३८६.३१	३३८६.३१
			१३०८८.४९
७५)	(२.२२)	(०.५४)	(२.८६)

करण्यात आले.
त्रैमासिक वित्तीय निष्कर्षाचे सविस्तर नमुन्यातील उतारा आहे.
माईटवर उपलब्ध आहे.

किसान मोलिंग्ज लिमिटेडकरिता
सही/-
संजीव अगरवाल
अध्यक्ष व व्यवस्थापकीय संचालक
(डीआयएन:०००६४०७६)

INDUSTRIES LIMITED

Indavarkar Road, Borivali (w), Mumbai - 400 092.
LC257750 / Phone : 022-4023 5742
dlttd.co.in / Website: www.srkindltd.co.in

UN-AUDITED FINANCIAL RESULTS FOR QUARTER ENDED 30.06.2019

	(Rs. In Lakhs)		
	Quarter Ended		Year Ended on
	30.06.2019	3.06.2018	31.03.2019
	Audited	Audited	Audited
Optional	3109.74	2453.23	11538.81
Optional	(49.11)	(44.01)	(116.24)
Optional	(49.11)	(44.73)	(116.24)
	(16.23)	14.21	(36.24)
shown in	(16.23)	14.21	(36.24)
try (items)	3922.67	3922.67	3922.67
			245.54
	(0.02)	0.02	(0.05)

Audited Financial Results for quarter ended on 30.06.2019 on 33 of the SEBI (LODR) Regulations, 2015. The full format of the Stock Exchange websites viz www.bseindia.com and

Audit Committee and approved by Board of Directors at their auditors have carried out an audit of the above results.

for S.R.K. Industries Limited
Rakeshchand M.Jain
Managing director

CLIO INFOTECH LTD

CIN: L65990MH1992PLC067450
Regd. Office no.901/902, 9th Floor, Allanta Centre, Opp.Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai. Tel.: 022-43211861, Email: clio_infotech@yahoo.com | Website: www.clioinfo.com

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED 30TH JUNE, 2019

Sr. No.	Particulars	(Rs. in Lacs)			
		Quarter ended	Quarter ended	Quarter ended	Year ended
		30.06.19 (Unaudited)	30.06.18 (Unaudited)	31.03.19 (Audited)	31.03.19 (Audited)
1	Total income from operations	4.65	1.75	2.82	8.24
2	Net Profit/Loss for the period (before tax, Exceptional and/or Extraordinary items)	(19.62)	(5.24)	(12.92)	(19.48)
3	Net Profit/Loss for the period before tax (after Exceptional and/or Extraordinary items)	(19.62)	(5.24)	(12.92)	(19.48)
4	Net Profit/Loss for the period after tax (after Exceptional and/or Extraordinary items)	(19.63)	(5.24)	(12.93)	(19.52)
5	Total Comprehensive income for the period [Comprising profit/(loss) for the period (after tax) and Other Comprehensive income (after tax)]	(19.67)	(5.24)	(12.93)	(19.70)
6	Paid up Equity Capital (Face Value of Rs.10/- each)	1101.10	1101.10	1101.10	1101.10
7	Earnings Per Share (EPS) in Rs. (Not Annualized)				
a.	Basic & Diluted EPS before extraordinary items	-0.18	(0.05)	(0.12)	(0.18)
b.	Basic & Diluted EPS after extraordinary items	-0.18	(0.05)	(0.12)	(0.18)

Note: The above is an extract of the detailed format of Quarterly Un-Audited Financial Results filed with Bombay Stock Exchange Limited under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015.

The full format of the Financial Results are available on the following website:
1) On the BSE Limited website: www.bseindia.com
2) On Company's website: www.clioinfo.com

Date: 13/08/2019
Place: Mumbai

By Order of the Board of Directors
For Clio infotech Limited
Sd/-
Suresh Bafna
Managing Director
DIN: 01569163



FREDUN PHARMACEUTICALS LIMITED

CIN: L24239MH1987PLC043662
Registered Office: 26, Manoj Industrial Premises, G.D. Ambekar Marg, Wadala, Mumbai - 400 031
Phone Number: +91 22 4031 8111 | Fax: +91 22 4031 8133
Email: business@fredungroup.com | Website: www.fredungroup.com

EXTRACT OF THE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2019*

Sr. No.	Particulars	(Rs. In Lakhs)			
		Quarter Ended		Year ended	
		June 2019 (Unaudited)	March 2019 (Audited)	June 2018 (Unaudited)	March 2019 (Audited)
1.	Total Income from Operations	2832.41	3222.86	1651.73	9740.30
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	23.34	282.02	(62.94)	616.18
3.	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	23.34	282.02	(62.94)	616.18
4.	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	23.34	111.84	(62.94)	446.00
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	23.34	111.84	(62.94)	446.00
6.	Equity Share Capital	398.96	398.96	344.72	398.96
7.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	3499.95
8.	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations) -				
1.	Basic:	0.59	2.80	00	11.17
2.	Diluted:	0.59	2.80	00	11.17

Note:
* This is in reference to our Newspaper article published yesterday i.e., August 14, 2019 wherein inadvertently the extracts were titled for March 2019. The title shall be read as "Extract of the Unaudited Financials for the Quarter ended June 30, 2019".

a) The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the website of the BSE Ltd. at www.bseindia.com and of the Company at www.fredungroup.com

b) # - Exceptional and/or Extraordinary Items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules / AS Rules, whichever is applicable.

Place : Mumbai
Date : August 13, 2019

For Fredun Pharmaceuticals Limited
Sd/-
Daulat Medhora
Jt. Managing Director